Great Lakes Advisors LLC Trims Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Great Lakes Advisors LLC trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 44,245 shares of the medical equipment provider’s stock after selling 5,714 shares during the quarter. Great Lakes Advisors LLC owned about 0.06% of Lantheus worth $3,958,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB purchased a new position in Lantheus during the third quarter worth about $25,000. Kestra Investment Management LLC bought a new stake in Lantheus during the fourth quarter worth about $27,000. UMB Bank n.a. lifted its stake in Lantheus by 31.5% during the fourth quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the last quarter. RiverPark Advisors LLC bought a new stake in Lantheus during the third quarter worth about $74,000. Finally, Parkside Financial Bank & Trust lifted its stake in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. This represents a 2.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the company’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Trading Up 1.8 %

NASDAQ LNTH opened at $101.10 on Friday. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The stock has a 50-day moving average of $91.87 and a 200-day moving average of $96.90. The firm has a market cap of $6.92 billion, a PE ratio of 16.82 and a beta of 0.38.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The business had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LNTH. Truist Financial lifted their price target on Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research note on Thursday, February 27th. The Goldman Sachs Group began coverage on Lantheus in a research note on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target for the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.